To screen ETFs by asset class, performance, yield and more, check out the
This user currently has no profile.
I graduated from the Univ. of Pittsburgh School of Pharmacy in 2000 and have worked in the profession for 13 years, including a pharmacy practice residency. I now am department chair of pharmacy technology at National College-Youngstown, Ohio. I have been investing on my own in the stock market for over 18 years.
Dividend stock ideas & income, Gold, Options, REITs, Retirement savings, Stocks - long, Tech stocks
Currently, there is no company profile for thepharmd.
Currently, there are no blog details for thepharmd.
Currently, there are no book details for thepharmd.
What do you make of the rec...
4 Convincing Reasons Why Gilead Sciences Should...
First and formost, I am a $...
Sovaldi And Drug Pricing: The United States Of ...
When it costs (on average $...
U.S. insurers get indigestion from high drug pr...
This is an antisense oligon...
Celgene licenses Crohns treatment for at least ...
What about Kalydeco? It's c...
House Democrats target Gilead for high price of...
Xignite quote data
© 2014 Seeking Alpha